Evidence map›Paper›PMID 33662297›Full record

ArticleThe Lancet. Oncology2021

Interpreting the RAPIDO trial: factors to consider - Authors' reply.

Renu R Bahadoer, Esmée A Dijkstra, Boudewijn van Etten, Corrie A M Marijnen, Hein Putter, Elma Meershoek-Klein Kranenbarg, Per J Nilsson, Bengt Glimelius, Cornelis J H van de Velde, Geke A P Hospers

Registry-linked trialAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in The Lancet. Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01558921 (Randomized Multicentre Phase III Study of Short Course Radiation Therapy Followed by Prolonged Pre-operative Chemotherapy and Surgery in Primary High Risk Rectal Cancer Compared to Standard Chemoradiotherapy and Surgery and Optional Adjuvant Chemotherapy.), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01558921 phase3active not recruitingnot on this map

Randomized Multicentre Phase III Study of Short Course Radiation Therapy Followed by Prolonged Pre-operative Chemotherapy and Surgery in Primary High Risk Rectal Cancer Compared to Standard Chemoradiotherapy and Surgery and Optional Adjuvant Chemotherapy.

TypeinterventionalSponsorUniversity Medical Center GroningenRan2011 to 2026Enrolled920ConditionsRectal CancerArmsM1 scheme, standard long course chemoradiotherapy
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Renu R BahadoerDepartment of Surgery, Leiden University Medical Center, Leiden, Netherlands.
Esmée A DijkstraDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen 9700 RB, Netherlands.
Boudewijn van EttenDepartment of Surgery, University Medical Center Groningen, University of Groningen, Groningen 9700 RB, Netherlands.
Corrie A M MarijnenDepartment of Radiation Oncology, Leiden University Medical Center, Leiden, Netherlands; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Hein PutterDepartment of Biomedical Datasciences, Leiden University Medical Center, Leiden, Netherlands.
Elma Meershoek-Klein KranenbargDepartment of Surgery, Leiden University Medical Center, Leiden, Netherlands.
Per J NilssonDepartment of Surgery, Karolinska University Hospital, Stockholm, Sweden.
Bengt GlimeliusDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Cornelis J H van de VeldeDepartment of Surgery, Leiden University Medical Center, Leiden, Netherlands.
Geke A P HospersDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen 9700 RB, Netherlands. Electronic address: g.a.p.hospers@umcg.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ChemoradiotherapyRectal NeoplasmsChemotherapy, AdjuvantHumansRectum

Identifiers

PMID33662297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.